Loading...
AbCellera reported Q4 2023 revenue of $9.2 million, representing 24% of the total revenue for 2023. The company experienced a net loss of $47.2 million, or $(0.16) per share. They advanced two internal programs into IND-enabling studies and saw three partner-initiated programs start with downstreams.
Q4 revenue was $9.2 million, 24% of total revenue for 2023.
$8.7 million was generated from research fees.
Net loss for Q4 was $47.2 million, or $(0.16) per share.
Advanced two internal programs into IND-enabling studies: ABCL635 and ABCL575.
AbCellera is shifting capital allocation from building capabilities to using them, which includes advancement of our first internal programs and strategic partnerships.